ClinicalTrials.Veeva

Menu

Molecular Endotype-Specific Dynamics of Lung Endothelial Barrier Integrity in Sepsis (MENDSEP)

M

Mater Dei Hospital, Malta

Status

Enrolling

Conditions

Pneumonia
Septic Shock
Sepsis

Treatments

Diagnostic Test: Blood transcriptomics and BAL protein profiling

Study type

Observational

Funder types

Other

Identifiers

NCT06287684
ESICM-22

Details and patient eligibility

About

Sepsis is a complex syndrome that causes lethal organ dysfunction due to an abnormal host response to infection. No drug specifically targeting sepsis has been approved. The heterogeneity in sepsis pathophysiology hinders the identification of patients who would benefit, or be harmed, from specific therapeutic interventions. Recent clinical genomics studies have shown that sepsis patients can be stratified as molecular endotypes, or subclasses, with important clinical implications. Classifying sepsis patients as molecular endotypes revealed that a poor prognosis endotype was characterized by immunosuppression and septic shock. Against this backdrop, the study hypothesis is that a poor prognosis for sepsis is defined by a molecular endotype reflecting impaired innate immune and endothelial barrier integrity in the primary anatomical site of infection.

Enrollment

132 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years
  • Acute respiratory tract infection due to community- or hospital-acquired pneumonia

Exclusion criteria

  • Consent card not signed
  • Pregnancy
  • Prisoners
  • Aspiration pneumonitis
  • Patients with ventilator-associated pneumonia

Trial contacts and locations

1

Loading...

Central trial contact

Carmel Abela, M.D.; Brendon Scicluna, Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems